Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Abstract Background This study aimed to evaluate the efficacy, side-effects and resistance mechanisms of first-line afatinib in a real-world setting. Methods This is a multicenter observational study of first-line afatinib in Malaysian patients with epidermal growth factor receptor (EGFR)-mutant adv...

Full description

Bibliographic Details
Main Authors: Gwo-Fuang Ho, Chee-Shee Chai, Adlinda Alip, Mohd Ibrahim A. Wahid, Matin Mellor Abdullah, Yoke-Ching Foo, Soon-Hin How, Adel Zaatar, Kai-Seng Lam, Kin-Wah Leong, John-Seng-Hooi Low, Mastura Md Yusof, Erica Chai-Yong Lee, Yok-Yong Toh, Chong-Kin Liam
Format: Article
Language:English
Published: BMC 2019-09-01
Series:BMC Cancer
Subjects:
Afatinib
Dose adjustment
Epidermal growth factor receptor (EGFR)
Real-world
Tyrosine kinase inhibitor
Online Access:http://link.springer.com/article/10.1186/s12885-019-6107-1

Internet

http://link.springer.com/article/10.1186/s12885-019-6107-1

Similar Items